As a monotherapy for type 2 diabetes patients, Sitagliptin phosphate monohydratecan significantly reduce the level of hemoglobin a1c (HbA1c).
*The following content is generated by AI and is for reference only.
Overview
Sitagliptin phosphate monohydrate is the stable salt form of a dipeptidyl peptidase-4 (DPP-4) inhibitor. Synthesized via catalytic hydrogenation and phosphoric acid neutralization, it features the molecular formula C16H19F6N5O8P and CAS No. 654670-26-3.
Application
- Pharmaceutical Manufacturing: Primary API for Type 2 diabetes management.
- Formulation Development: Used in tablet and capsule production for oral administration.
- Quality Control: Standard reference material for HPLC assay validation.
Precautions
Store under controlled room temperature with low humidity to prevent hydrolysis. Handle with PPE to avoid inhalation or skin contact; contraindicated in severe renal impairment without dosage adjustment.